 OCALA, Fla., Sept. 08, 2021 GLOBE NEWSWIRE -- AIM ImmunoTech Inc. NYSE American: AIM today announced that is has submitted a Pre-Investigational New Drug application Pre-IND to the U.S. Food and Drug Administration FDA for a Phase 2 clinical study of Ampligen as a potential infusion therapy for Post-COVID-19 Cognitive Dysfunction PCCD. 